Whitehawk Therapeutics (WHWK)
Develops in-licensed antibody-drug conjugates for cancer treatment.
Something off on this page? Send us feedback.
Develops three in-licensed ADC candidates for cancer treatment: PTK7-targeted HWK-007, MUC16-targeted HWK-016, and SEZ6-targeted HWK-206. Having sold FYARRO, it is focused on clinical development, with progress tied to FDA clearance, trial execution, and manufacturing.
Develops antibody-drug conjugates, or ADCs, for cancer treatment. Its portfolio includes PTK7-targeted HWK-007, MUC16-targeted HWK-016, and SEZ6-targeted HWK-206, all in-licensed from WuXi Biologics. The candidates address established tumor targets under a global development and commercialization license from WuXi Biologics.
HWK-007 and HWK-016 are in actively recruiting Phase 1 trials, while HWK-206 was expected to enter IND review in mid-2026. After selling the FYARRO business, it focuses on clinical development rather than commercial operations.
The operating model depends on FDA clearance, trial execution, and manufacturing and IND-enabling studies proceeding on schedule.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $190.0M · Total debt $0 · Total assets $194.0M · Shareholders' equity $182.9M
- Revenue
- $0
- Operating income
- −$18.1M
- Net income
- −$16.6M
No dividends on record.
| Insiders | 2.89% | 1.65M shares | |
|---|---|---|---|
| 5 holders · as of May 18, 2026 | |||
| Strategic holders | 8.29% | 4.73M shares | |
| 1 holder · as of Mar 11, 2025 | |||
| Other | 88.82% | 50.64M shares | |
| remainder | |||
57.01M company shares as of Aug 21, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Suvretta Capital Management, LLCStrategic | 8.29% | 4.73M | filed Mar 11, 2025 |
OrbiMed Advisors LLCInstitution | 7.31% | 4.17M | filed May 15, 2025 |
Coastlands Capital LPInstitution | 4.95% | 2.82M | filed Aug 25, 2025 |
David James LennonInsiderdirector, officer: CHIEF EXECUTIVE OFFICER | 1.00% | 569,643 | filed May 18, 2026 |
Bryan BallInsiderofficer: See remarks | 0.79% | 448,126 | filed May 18, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Scott M. Giacobello | officer: CHIEF FINANCIAL OFFICER | −141,600 | $4.13 |
| Apr 15, 2026 | Scott M. Giacobello | officer: CHIEF FINANCIAL OFFICER | −77,000 | $3.86 |
| Apr 14, 2026 | Bryan Ball | officer: See remarks | −92,460 | $3.64 |
| Apr 13, 2026 | Bryan Ball | officer: See remarks | −26,389 | $3.46 |
| Apr 10, 2026 | Bryan Ball | officer: See remarks | −6,596 | $3.43 |
- Eli Lilly
Phase 1 PTK7 ADC rival in lung and endometrial cancer
- ArriVent BioPharma
IND-cleared MUC16/NaPi2b ADC rival in ovarian and endometrial cancer
- AbbVie
Clinical-stage SEZ6 ADC rival for small-cell lung cancer
- Regeneron
MUC16-targeted immunotherapy rival in ovarian cancer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics | $3.85 | −4.83% | $230.3M | — | — | — | — |
| Eli Lilly | $1,156.36 | −1.18% | $1.10T | 39.3 | 28.3 | 13.8 | +47.7% |
| ArriVent BioPharma | $30.32 | +0.00% | $1.41B | — | — | — | — |
| AbbVie | $265.20 | −0.01% | $468.77B | 74.8 | 17.5 | 7.3 | +10.2% |
| Regeneron | $802.87 | −0.13% | $82.82B | 19.9 | 13.3 | 5.3 | +16.7% |
| Median | 39.3 | 17.5 | 7.3 | +16.7% |